These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 16899622

  • 1. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
    Badn W, Kalliomäki S, Widegren B, Sjögren HO.
    Clin Cancer Res; 2006 Aug 01; 12(15):4714-9. PubMed ID: 16899622
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.
    Badn W, Hegardt P, Fellert MA, Darabi A, Esbjörnsson M, Smith KE, Janelidze S, Salford LG, Visse E, Siesjö P.
    Scand J Immunol; 2007 Mar 01; 65(3):289-97. PubMed ID: 17309784
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas.
    Hegardt P, Widegren B, Sjögren HO.
    Cell Immunol; 2000 Mar 15; 200(2):116-27. PubMed ID: 10753503
    [Abstract] [Full Text] [Related]

  • 8. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
    Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB.
    Thyroid; 2002 Dec 15; 12(12):1063-70. PubMed ID: 12593719
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
    Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE.
    Clin Cancer Res; 2001 Apr 15; 7(4):1052-60. PubMed ID: 11309357
    [Abstract] [Full Text] [Related]

  • 12. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
    Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH.
    Clin Cancer Res; 2009 Jul 01; 15(13):4484-92. PubMed ID: 19549771
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats.
    Ke Q, Bodyak N, Rigor DL, Hurst NW, Chaplin DJ, Kang PM.
    Vascul Pharmacol; 2009 Jul 01; 51(5-6):337-43. PubMed ID: 19737629
    [Abstract] [Full Text] [Related]

  • 14. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 15. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
    Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ.
    Cancer Res; 1999 Apr 01; 59(7):1626-34. PubMed ID: 10197639
    [Abstract] [Full Text] [Related]

  • 16. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z, Yan F, Wang YS, Liu HY, Gou LT, Zhao XY, Lai ST, Deng HX, Li J, Ding ZY, Xiong SQ, Kan B, Mao YQ, Chen LJ, Wei YQ, Zhao X.
    Cancer Chemother Pharmacol; 2009 Dec 01; 65(1):13-25. PubMed ID: 19387645
    [Abstract] [Full Text] [Related]

  • 17. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
    McPhail LD, Griffiths JR, Robinson SP.
    Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1238-45. PubMed ID: 17967313
    [Abstract] [Full Text] [Related]

  • 18. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
    Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D.
    J Clin Endocrinol Metab; 2007 Aug 15; 92(8):2902-9. PubMed ID: 17550961
    [Abstract] [Full Text] [Related]

  • 20. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
    Shnyder SD, Cooper PA, Pettit GR, Lippert JW, Bibby MC.
    Anticancer Res; 2003 Aug 15; 23(2B):1619-23. PubMed ID: 12820431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.